Navigation Links
DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results

CUPERTINO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2007. Total revenues were $6.6 million for the three months ended December 31, 2007, compared to $5.4 million for the same period in 2006. Net loss for the three months ended December 31, 2007 was $7.2 million, compared to a net loss of $9.8 million for the same period in 2006.


For the fiscal year ended December 31, 2007, total revenues were $30.7 million, compared to $21.9 million for the same period in 2006. Net loss for the year ended December 31, 2007 was $24.3 million, compared to a net loss of $33.3 million for the same period in 2006.

At December 31, 2007, DURECT had cash and investments of $62.0 million, compared with cash and investments of $81.6 million at December 31, 2006; these figures include restricted investments of $1.0 million at December 31, 2007 and $1.3 million at December 31, 2006. DURECT's net decrease in cash during 2007 was $19.6 million.

"DURECT's pipeline advanced during 2007, reporting positive clinical trial results for three programs in Phase III or II. We expect to continue this progress in 2008 as we look forward to the filing of the first New Drug Application (NDA) based on our ORADUR(TM) technology and further advancing our late stage programs," stated James E. Brown, D.V.M., President and CEO of DURECT. "Remoxy(TM) met the primary endpoint in its pivotal Phase III study conducted under a Special Protocol Assessment (SPA), POSIDUR(TM) reported statistically significant improvements in pain control while reducing the use of narcotics in a Phase IIb hernia study, and ELADUR(TM) showed improved pain control versus placebo over the three day treatment period in a Phase IIa study. Each of these programs addresses large market opportunities with product features that offer clear advantages over existing therapeutics."
Highlights for DURECT in Fiscal Year 2007 include:

-- Remoxy. In December, our collaborators King Pharmaceuticals and Pain

Therapeutics announced that the pivotal Phase III trial for Remoxy

successfully met its primary endpoint (p<0.01) that was prospectively

defined by the U.S. Food and Drug Administration (FDA) during the SPA

process. In addition, the study achieved statistically significant

results in secondary endpoints such as Quality of Analgesia (p<0.01)

and Global Assessment (p<0.01). No drug related safety issues were

noted in the study.

Remoxy is an abuse-resistant, long-acting form of oxycodone based on

our ORADUR(TM) technology intended for the treatment of chronic pain.

-- POSIDUR Post-Operative Pain Relief Depot. In July, we announced

positive results from a 122 patient Phase IIb clinical trial in which

POSIDUR at a dose of 5 mL demonstrated statistically significant

reductions in post-operative pain (by approximately 30% versus placebo)

and in total consumption of supplemental opioid analgesic medications

(approximately 3x less versus placebo) in patients undergoing inguinal

hernia repair. These successful results triggered an $8 million

milestone payment by Nycomed to DURECT under the parties' international

collaborative agreement. We have held an end-of-Phase II meeting with

the U.S. Food & Drug Administration (FDA) and are in dialogue with the

FDA regarding the Phase III program. Hospira, our manufacturer of

POSIDUR, has produced supplies for Phase III clinical trials.

POSIDUR is our post-operative pain relief depot that utilizes our

patented SABER(TM) technology to deliver bupivacaine to provide up to

three days of pain relief after surgery. POSIDUR is licensed to Nycomed

for commercialization in Europe and select other countries, and DURECT

has retained commercialization rights in the US, Canada and Asia.

-- ELADUR (TRANSDUR(TM)-Bupivacaine). In December, we announced positive

results from a 60 patient Phase IIa clinical trial. In this study of

patients suffering from post-herpetic neuralgia, ELADUR showed improved

pain control versus placebo during the 3-day continuous treatment

period. In addition, ELADUR appeared to be well tolerated overall, and

patients treated with ELADUR and placebo exhibited similar safety

profiles. We have in place a relationship with Corium International,

whereby Corium will be our worldwide supplier of ELADUR patches.

ELADUR is our proprietary transdermal patch intended to provide

bupivacaine for a period of up to three days from a single application.

We retain full commercial rights to this drug candidate.

-- TRANSDUR-Sufentanil. Endo Pharmaceuticals, our licensee for

commercialization in the US and Canada, has publicly disclosed that

they have commenced their Phase II program in June 2007.

TRANSDUR-Sufentanil is our proprietary transdermal patch intended to

provide sufentanil to chronic pain sufferers for a period of up to

seven days from a single application.

-- Expansion of Patent Portfolio. In the fourth quarter of 2007, we

acquired from a third party a portfolio of worldwide patents relating

to drug delivery technologies. This portfolio consists of

approximately 22 issued and pending U.S. patents and patent

applications as well as their international counterparts. We believe

this portfolio will benefit our business by broadening our drug

delivery technology base and strengthening our intellectual property


-- Reduction in Convertible Notes. We reduced the balance of our

outstanding convertible notes from $37.3 million at December 31, 2006

to $23.6 million as of December 31, 2007 by paying a small premium over

the future interest payments due on these notes in order to induce

early conversion. The outstanding convertible notes will mature on

June 15, 2008, if not converted earlier.

Financial Guidance for 2008 and Major Potential Milestones Over the Next 12-18 Months

-- Financial Guidance. Our net cash consumption is heavily influenced by

the timing and structure of new corporate collaborations, as well as

the achievement of milestones under existing collaborations. While we

anticipate entering into new collaborations in 2008 and beyond,

assuming no new collaborations, no milestone payments and aggressive

funding of our R&D programs, many of which are in clinical development,

we anticipate our net cash consumption in 2008 will be approximately

$32-36 million.

-- Business Development Activities. We have multiple late stage programs

that may potentially be partnered over the next 12-18 months. These

include ELADUR, TRANSDUR-Sufentanil for Europe and for Asia, POSIDUR

for Asia, as well as various internal programs which we have not

described publicly in detail.

-- Remoxy. Our collaborator, Pain Therapeutics, has stated that they

expect to file the NDA for Remoxy in Q2 2008.

-- POSIDUR. We are continuing our dialogue with the FDA regarding our

Phase III program, upon completion of which we plan to commence that


-- ELADUR. We are conducting manufacturing scale-up and processing to

secure Phase III supplies, and are developing our clinical and

regulatory strategy.

-- TRANSDUR-Sufentanil Patch. Endo Pharmaceuticals is continuing to

conduct Phase II studies with TRANSDUR-Sufentanil designed to evaluate

the conversion of patients on oral opioids to TRANSDUR-Sufentanil.

About DURECT Corporation

DURECT Corporation is an emerging specialty pharmaceutical company developing pharmaceutical systems based on its proprietary drug delivery platform technologies. The Company currently has a number of late-stage pharmaceutical products in development addressing large markets in pain management, with a number of research programs underway targeting chronic disease and other therapeutic areas. For more information, please visit

NOTE: POSIDUR(TM), SABER(TM), ORADUR(TM), TRANSDUR(TM) and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.

DURECT Forward-Looking Statement

The statements in this press release regarding the anticipated filing of an NDA for Remoxy, our anticipated commencement of the Phase III program for POSIDUR, our possible entry into future collaborative agreements and our projected financial results as well as other statements regarding DURECT's products in development, product development plans, anticipated regulatory, clinical and development milestones and timing thereof, future clinical trial results, our business development intentions and DURECT's emergence as a specialty pharmaceutical company are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, DURECT's (and that of its third party collaborators where applicable) abilities to obtain approvals from regulatory agencies with respect to its development activities and products, design, enroll, conduct and complete clinical trials, complete the design, development, and manufacturing process development of the referenced product candidates, consummate collaborative agreements relating to our product candidates and technologies, manufacture and commercialize the referenced product candidates, obtain marketplace acceptance of the referenced product candidates and manage and obtain capital to fund its growth, operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q on November 8, 2007 under the heading "Risk Factors."



(in thousands, except per share amounts)


Three months ended Year Ended

December 31, December 31,

2007 2006 2007 2006

Collaborative research and

development revenue $4,559 $3,522 $14,417 $13,786

Milestone revenue - - 8,000 -

Product revenue, net 2,026 1,919 8,258 8,108

Total revenues 6,585 5,441 30,675 21,894

Operating expenses:

Cost of revenues (1) 807 983 3,225 3,248

Research and development (1) 9,502 11,598 38,342 37,241

Selling, general and

administrative (1) 3,262 2,877 13,618 12,417

Amortization of intangible

assets 8 8 31 424

Total operating expenses 13,579 15,466 55,216 53,330

Loss from operations (6,994) (10,025) (24,541) (31,436)

Other income (expense):

Interest and other income 753 991 3,545 3,832

Interest expense (475) (717) (2,625) (3,436)

Debt conversion expense (495) - (718) (2,287)

Net other income (expense) (217) 274 202 (1,891)

Net loss $(7,211) $(9,751) $(24,339) $(33,327)

Net loss per share, basic and

diluted $(0.10) $(0.14) $(0.35) $(0.51)

Shares used in computing basic and

diluted net loss per share 73,641 68,980 70,483 65,961

(1) Includes stock-based

compensation related to the


Cost of revenues $32 $28 $130 $75

Research and development 995 801 4,286 2,885

Selling, general and administrative 553 420 2,273 1,431

Total stock-based compensation $1,580 $1,249 $6,689 $4,391


Condensed Balance Sheet

(in thousands)

As of As of

December 31, December 31,

2007 2006 (1)



Current assets:

Cash and cash equivalents $37,589 $41,554

Short-term investments 19,710 28,297

Accounts receivable 3,622 2,152

Inventories 1,963 2,052

Prepaid expenses and other current assets 1,904 1,744

Total current assets 64,788 75,799

Property and equipment, net 7,658 7,451

Goodwill 6,399 6,399

Intangible assets, net 180 111

Long-term investments 3,697 10,472

Restricted Investments 1,020 1,284

Other non-current assets 278 969

Total assets $84,020 $102,485


Current liabilities:

Accounts payable $1,834 $864

Accrued liabilities 5,499 4,522

Contract research liability 1,946 1,624

Interest payable on convertible notes 61 97

Deferred revenue, current portion 5,728 5,348

Equipment financing obligations, current portion 38 34

Bonds payable, current portion 225 210

Convertible subordinated notes due 2008 23,599 -

Other short-term liabilities 158 -

Total current liabilities 39,088 12,699

Bond payable and equipment financing obligations,

noncurrent portion 343 606

Convertible subordinated notes due 2008 - 37,337

Deferred revenue, noncurrent portion 9,268 14,507

Other long-term liabilities 740 304

Stockholders' equity 34,581 37,032

Total liabilities and stockholders' equity $84,020 $102,485

(1) Derived from audited financial statements.

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
2. DURECT to Host Webcast in Conjunction with an Analysts Day on October 17
3. DURECT Corporation Invites You to Join Its Fourth Quarter 2007 Earnings Conference Call
4. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
7. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
8. BioElectronics Corporation Announces Singapore and Malaysia Sales
9. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
10. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
11. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
(Date:10/12/2017)... ... 12, 2017 , ... BioMedGPS announces expanded coverage of SmartTRAK ... module, US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats and Sealants ... sealants and biologic sealants used in surgical applications. BioMedGPS estimates the market will ...
(Date:10/11/2017)... ... October 11, 2017 , ... At ... Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist ... has been selected for membership in ARCS Alumni Hall of Fame . ...
(Date:10/11/2017)... ... 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th year. ... San Francisco, CA. The Summit brings together current and former FDA office bearers, regulators, ... government officials from around the world to address key issues in device compliance, quality ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
Breaking Biology Technology:
(Date:4/5/2017)... -- The Allen Institute for Cell Science today announces the ... and dynamic digital window into the human cell. The ... of deep learning to create predictive models of cell ... growing suite of powerful tools. The Allen Cell Explorer ... available resources created and shared by the Allen Institute ...
(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
Breaking Biology News(10 mins):